Gmyterco Vanessa Cunningham, Luciano Fernando Bittencourt, Ludwig Lucas André, Evangelista Alberto Gonçalves, Ferreira Tássia Sell, Borek Fernanda, de Farias Marconi Rodrigues
Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil.
Vet Dermatol. 2025 Apr;36(2):137-147. doi: 10.1111/vde.13323. Epub 2025 Jan 8.
Chronic and recurrent pyoderma in dogs is driving a growing interest in natural antimicrobial products that offer minimal adverse effects and avoid antibiotic resistance.
Evaluate the safety and efficacy of dermatological products with antimicrobial peptides and plant extracts, comparing them to chlorhexidine + miconazole and cephalexin therapy for superficial pyoderma in dogs.
Forty-five dogs with superficial pyoderma underwent clinical, cytopathological and microbiological diagnosis, and were randomly assigned to Group 1 (G1) treated with shampoo (two weekly baths) and lotion (twice daily on the affected areas) containing natural antimicrobials; Group 2 (G2) treated with two weekly baths using a therapeutic shampoo containing 2% chlorhexidine and 2.5% miconazole; or Group 3 (G3) treated with oral cephalexin 30 mg/kg twice daily. Staphylococcus spp. strains were identified using matrix-assisted laser desorption ionisation-time of flight mass spectrometry and pruritus Visual Analog Scale (PVAS)/lesion scores were evaluated on Day (D)0, D7, D14, D21 and D28.
Statistical differences (p < 0.05) were noted between D0 and D28 in PVAS values and lesion scores for all groups. G1 had lower PVAS scores than other groups on D7 and D14 (p < 0.05) and lower lesion scores than G3 on D7. By D28, G1 and G3 had lower lesion scores than G2. Notably, G1 and G2 had no adverse effects, while 26% of G3 patients experienced gastrointestinal issues during therapy.
This preliminary investigation of the new product (G1) suggests that it is effective, safe and a promising topical treatment for managing superficial pyoderma in dogs, offering an alternative to systemic antibiotics and topical antiseptic treatments.
犬类慢性复发性脓皮病促使人们对不良反应最小且能避免抗生素耐药性的天然抗菌产品越来越感兴趣。
评估含抗菌肽和植物提取物的皮肤科产品的安全性和有效性，并将其与洗必泰+咪康唑及头孢氨苄治疗犬浅表脓皮病的效果进行比较。
45只患有浅表脓皮病的犬接受了临床、细胞病理学和微生物学诊断，并被随机分为三组：第1组（G1），使用含天然抗菌剂的洗发水（每周两次洗澡）和乳液（每日两次涂抹于患部）进行治疗；第2组（G2），使用含2%洗必泰和2.5%咪康唑的治疗性洗发水每周洗澡两次；第3组（G3），口服头孢氨苄，剂量为30mg/kg，每日两次。使用基质辅助激光解吸电离飞行时间质谱法鉴定葡萄球菌属菌株，并在第0天（D0）、第7天、第14天、第21天和第28天评估瘙痒视觉模拟量表（PVAS）/皮损评分。
所有组在D0和D28之间的PVAS值和皮损评分存在统计学差异（p<0.05）。G1组在第7天和第14天的PVAS评分低于其他组（p<0.05），在第7天的皮损评分低于G3组。到第28天，G1组和G3组的皮损评分低于G2组。值得注意的是，G1组和G2组没有不良反应，而G3组26%的患者在治疗期间出现胃肠道问题。
对新产品（G1）的这项初步研究表明，它是一种有效、安全且有前景的局部治疗方法，可用于治疗犬浅表脓皮病，为全身用抗生素和局部抗菌治疗提供了一种替代方案。
